Qiagen Nv

revealed that they own a 13.1% stake in HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) in a Schedule 13G/A disclosure that was filed with the Securities and Exchange Commission on Wednesday, November 8th. The investor owns 1,586,355 shares of the stock worth approximately $4,045,205. The reporting parties listed on the disclosure included Qiagen Nv and QIAGEN North American Holdings, Inc. The filing is available through Edgar at this link.

Separately, Vanguard Group Inc. lifted its position in shares of HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after buying an additional 37,841 shares in the last quarter. Institutional investors own 21.69% of the company’s stock.

In related news, major shareholder Holdings A/S Novo sold 1,149,813 shares of HTG Molecular Diagnostics stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $1.81, for a total value of $2,081,161.53. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold a total of 1,661,889 shares of company stock worth $3,077,980 in the last ninety days. 7.60% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/08/qiagen-nv-owns-13-1-stake-in-htg-molecular-diagnostics-inc-htgm.html.

HTG Molecular Diagnostics, Inc. (HTGM) traded up $0.31 during trading hours on Wednesday, hitting $2.55. 3,077,757 shares of the company were exchanged, compared to its average volume of 1,015,385. The company has a current ratio of 1.58, a quick ratio of 1.46 and a debt-to-equity ratio of -1.44. HTG Molecular Diagnostics, Inc. has a 52 week low of $1.20 and a 52 week high of $13.25.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, hitting analysts’ consensus estimates of ($0.60). The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.80 million. sell-side analysts expect that HTG Molecular Diagnostics, Inc. will post -2.15 EPS for the current year.

Several research firms have commented on HTGM. ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of HTG Molecular Diagnostics in a research report on Wednesday. Finally, Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.17.

HTG Molecular Diagnostics Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Stock Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related stocks with our FREE daily email newsletter.